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Objectives: Generic medicine prescribing has become a common practice in public hospitals. However, the
trend in private medical centres seems to be different. The objective of this study was to investigate knowledge,
perceptions and behavior of physicians from private medical centres in Malaysia regarding generic medicines.
Methods: This study was a cross-sectional nationwide survey targeting physicians from private medical centres
in Malaysia. The survey was conducted using questionnaire having (i) background and demographic data of the
physicians, volume of prescription in a day, stock of generic medicines in their hospital pharmacy etc. (ii) their knowledge
about bioequivalence (iii) prescribing behavior (iv) physicians’ knowledge of quality, safety and efficacy of generic
medicines, and their cost (v) perceptions of physicians towards issues pertaining to generic medicines utilization.
Results: A total of 263 questionnaires out of 735 were received, giving a response rate of 35.8%. Of the respondents, 214
(81.4%) were male and 49 (18.6%) were females. The majority of the participants were in the age range of 41–50 years
and comprised 49.0% of the respondents. Only 2.3% of physicians were aware of the regulatory limits of bioequivalence
standards in Malaysia. Of the respondents, 23.2% agreed that they ‘always’ write their prescriptions using originator
product name whereas 50.2% do it ‘usually’. A number of significant associations were found between their knowledge,
perceptions about generic medicines and their demographic characteristics.
Conclusions: The majority of the physicians from private medical centres in Malaysia had negative perceptions about
safety, quality and the efficacy of generic medicines. These negative perceptions could be the cause of the limited use of
generic medicines in the private medical centres. Therefore, in order to facilitate their use, it is recommended
that the physicians need to be reassured and educated about the drug regulatory authority approval system of
generic medicines with regard to their bioequivalence, quality, efficacy and safety. Apart from the policy on
generic substitution, it would also be recommended to have a national medicine pricing policy, which controls
drug prices, in both the public and private sector. These efforts are worthwhile to reduce the drug expenditure
and improve the medicine affordability in Malaysia.
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Malaysia has built a complex, but comprehensive health-
care system, that keeps a tab on every level of healthcare
related service in the country, from medical institutions
to the primary end user–the patient [1]. Malaysia has a
comprehensive two-tiered healthcare system that con-
sists of a government-run public sector and a private
healthcare sector. The public sector is heavily subsidised
by the government and represents about 70% of the
healthcare services and while the private sector is limited
to those who can afford it and represents about 30% of
the healthcare services [2]. In the public sector, the Min-
istry of health (MOH) is the main government body ac-
countable for providing healthcare services in the
country [3]. The private sector offers both remedial and
rehabilitation services and is financed strictly on a fee-
for-service basis. The cost is paid fully by patients them-
selves, their employers, and/or by their insurance com-
panies [3,4]. Despite their short history, private-for-
profit hospitals have been increasing at a very fast pace
in most developing countries including Malaysia [5]. To
date, the private healthcare providers dominate the mar-
ket, and a total of 62% of all hospitals are owned by pri-
vate entities [6]. This increasing demand is due to an
increase in income per capita following the deregulation
in the supply of healthcare services, an increase in the
awareness on the importance of healthcare, and access
to the Internet, resulting in an increased understanding
on the importance of the early treatment for critical dis-
eases [6]. In comparison to the public sector, these hos-
pitals have acquired state-of-the art machines, best
talent pool, English speaking staff, medical tourism pro-
motional packages and above all government has pro-
vided them incentives for expenses incurred in obtaining
international accreditations etc. [6,7]. All of these efforts
have today resulted in more than 225 private hospitals
which are expected to grow to 239 by 2018 [7].
With this insight into the Malaysian healthcare system,
it is prudent to know the financial side of this sector
with a special attention to private healthcare system. In
tandem, Malaysia’s healthcare expenditure is estimated
to reach nearly US$ 20.4 billion (bn) by 2018 [8]. The
Total Health Expenditure (TEH, nominal) for Malaysia
during 1997–2012 ranged from US$ 2.67bn in 1997 to
US$ 13.65bn in 2012. During the period of 1997–2012,
the share of private expenditure in overall healthcare ex-
penditure rose to 47% [9]. In 2013, private healthcare ex-
penditure reached US$ 6.47bn, representing 53.5% of the
total healthcare outlay in Malaysia [8]. Like most of the
developing countries, Malaysia does not have a national
social health insurance scheme. Private health insurance
is voluntary and is generally taken out mainly to cover
private health services. Private household out-of-pocket
payments (OOPPs) form the largest component ofprivate healthcare spendings [10,11]. In 2009, Malaysia’s
out-of-pocket (OOP) spending was 77% of private sector
spending, which is twice the high-income country OOP
average at 37% of private sector spending [12,13]. The
OOPPs contribution has gone up to an average of 79%
of the private sector’s expenditure in 2012 [9,14]. The
contribution of the expense on pharmaceuticals out of
this 79% OOPPs is not known. These OOPPs are set to
worsen as price increases are proposed both in terms of
specialist doctors’ fees and the prospect of pharmacists
charging for consultations [8]. One of the best docu-
mented barriers to medication adherence is high OOP
costs even among individuals with prescription drug in-
surance [15]. The government hospitals currently dis-
penses most drugs free of-charge, but patients who use
private sector pay for their medicine and these costs can
be substantial. Costs of medicines in the private sector
of Malaysia are higher than in the public sector. As dis-
pensing doctors and private retail pharmacies apply high
mark-up prices, the practice of price control and the
greater use of generic medicines are required to make
the medicines affordable to Malaysian public [16]. Above
all, medicine prices in the private market of Malaysia are
determined by market force, without any control by the
government. There is no national drug pricing policy ex-
ists and studies have reported that the prices of medi-
cines are high in Malaysia [17-19].
To bring down the OOPPs and reduce financial bur-
den on patients in private healthcare sector, it is highly
recommended to promote use of generic medicines [20].
This can allow considerable savings in health care cost
without affecting the quality or the therapeutic effect of
the prescribed medicine and will also reduce OOPPs
burden substantially [21-24]. The acceptance of generic
medicines in medical practices is a complex phenomenon
and many factors can influence it. Physicians play an
important role in controlling this phenomenon and
their decision in prescribing generic drugs is likely to
be affected by many determinants [25]. Although there
is increasing local and international encouragement for
physicians to prescribe generic medicines, some phy-
sicians are not in favor of prescribing them. Therefore,
many studies have tried to find determinants of this
practice [26-28]. In Malaysia, generic drug prescribing
has become a common practice in public hospitals.
However, there is a paucity of data regarding the per-
spectives of Malaysian private medical practitioners
regarding generic medicines. Therefore, the aim of this
study was to investigate knowledge, perception and be-
havior of physicians from private medical centres of
Malaysia regarding generic medicines and to examine
factors that affect their prescribing pattern regarding
choice of medicine brands (i.e. generic medicines and
innovator medicines).
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Study design: the study instrument/questionnaire
This survey was conducted using a self-completed an-
onymous questionnaire which was adopted and modified
from a previous study conducted by Chua, et al. [29].
The questionnaire was validated using an expert review
and a field evaluation by potential respondents [30,31].
The questionnaire was designed in order to elicit know-
ledge, perception, and behaviour of physicians towards
generic medicines. It contained 10 multiple-choice ques-
tions and an 18 Five-Point Likert Scale statements and
comprised 5 sections: (i) the background and the demo-
graphic data of the physicians, including their experi-
ence, their volume of prescriptions in a day, and the
stock of generic medicines in their hospital pharmacy,
etc. (ii) their knowledge about bioequivalence (iii) pre-
scription behaviour (iv) the physician’s knowledge and
beliefs regarding quality, safety and efficacy of generic
medicines, together with their cost in comparison to in-
novator products (v) the perceptions of the prescribers
to issues pertaining to generic medicine utilisation in
Malaysia.
Study participants and sampling
This nationwide survey targeted physicians working at
the private medical centres in Malaysia. Since the study
population was private medical centres, the member
hospitals registered with the Association of Private Hos-
pitals of Malaysia (APHM) as of May 2013, were consid-
ered as potential participants. Out of 114 hospitals
registered with the APHM, 95 hospitals were contacted
during the period of May 2013–June 2013. A total of 19
Hospitals having less than 15 beds, and centres which
only provide maternity services were excluded from this
study.
Survey administration
First of all, before conducting the survey, a letter of
introduction was sent to the President of the APHM,
seeking approval for the study, and informing its mem-
bers of the planned survey, and to prepare the potential
respondents for the survey. Then, along with the ap-
proval letter from the APHM, the final validated survey
questionnaire, with a cover letter were sent through or-
dinary mail, or electronic mail, to the Human Resources
Department (HRD), or the person in charge, of all 95
hospitals. The cover letter included a request for their
willingness to participate in the survey, explaining the
importance and the purpose of the study. Follow-up
telephone calls and electronic mail reminders were sent
to non-respondents. There was no response from 39
hospitals and 22 institutions declined to participate in
the study. The institutions that agreed to participate per-
mitted us to contact the physicians directly, or throughtheir HRD. The required copies of the questionnaire
were posted to the contact person of the participating
hospitals. The completed survey forms were collected by
the HRD of the hospitals, and sent to the researchers
through ordinary or electronic mail. However, for some
hospitals, the survey forms were distributed and col-
lected by the researchers.
Ethical consideration
Ethical approval for this study was obtained from the
ethical committee named “the Joint Ethics Committee of
the School of Pharmaceutical Sciences, USM–Hospital
Lam Wah Ee on Clinical Studies”, Penang, Malaysia
(USM-HLWE/IEC/2013(0004). Participation in the study
was voluntary and no compensation was paid to the par-
ticipants. The information received was anonymous and
treated confidentially.
Statistical analysis
The survey questionnaire was categorised into five re-
sponses (Strongly Agree=5, Agree=4, Neutral=3, Dis-
agree=2, and Strongly Disagree=1). The frequency and
the percentages were used for the descriptive analyses to
examine the characteristics of the respondents and the
responses for each question in the survey [32]. In order
to examine the associations between the physician’s
background, and the variables related to their knowledge
about generic medicines were assessed by using Mann
Whitney and Kruskal Wallis tests. All statistical tests
were conducted at an a priori significance level of
p<0.05 using Statistical Package for the Social Sciences
(SPSS) Version 16 for Windows.
Results
Demographic and practice characteristics
A total of 263 questionnaires out of 735 were received
by researchers from those hospitals who agreed to par-
ticipate in the study, giving a response rate of 35.8%.
However, this is the overall response rate, because the
effective response rate could not be measured as the sur-
vey form distribution and the collection was handled dir-
ectly by the HRDs of the many hospitals. Among all of
the respondents, 214 (81.4%) were males and 49 (18.6%)
were females. The majority of the participants were in
the age range of 41–50 years and comprised 49.0% of
the whole respondents. This age group of participants
graduated between the years 1991–2000. 51.7% of the
prescribers had a postgraduate degree and 55.5% were
graduated from Malaysia. 30.4% of the physicians had
been practising for more than 25 years and 39.9% of the
subjects had a prescription rate of 11–20 prescriptions
per day. Almost 57.0% of the respondents informed that
the stock of generic medicine in their hospital pharmacy
was less than 10%, whereas 29.3% of the respondents












































*Place of highest level of education was considered.
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The stock of generic medicines in the hospital pharma-
cies was more than 61%, according to 10.6% of the cases
only. The detailed demographic characteristics are pre-
sented in Table 1.
The doctor’s knowledge about the regulatory
bioequivalence standards for generic drug products
The physicians were requested to tick on the relevant an-
swer to a multiple choice question to identify the Malaysia’s
National Pharmaceutical Control Board (NPCB) bioequiva-
lence standard. An introductory statement was used to
explain the question as follows: ‘The NPCB, Malaysia con-
siders a product to be bioequivalent if its bioavailability is
within a specified range compared with the currently mar-
keted branded product. The regulatory limits applied are
that 90% confidence intervals for the ratios (generic prod-
uct: brand name product) of the areas under the plasma
drug concentration versus time curves and the maximum
plasma drug concentrations must fall between?’ The results
showed that only 2.3% of the respondents could answer it
correctly.
Prescribing behaviour of physicians
In the questions related to prescribing behaviour, 23.6%
of the respondents agreed that they ‘always’ write their
prescriptions using originator product names, whereas
49.4% of the physicians do it ‘usually’. Only 9.9% of the
physicians indicated that their prescription was ‘some-
times’ a brand name.
The knowledge about generic medicines
The responses received and the influences of demo-
graphic characteristics on physicians’ knowledge about
generic medicines are provided in Tables 2 and 3 re-
spectively. The possible associations between the beliefs
about generic medicines and the demographic character-
istics were assessed using Mann Whitney and Kruskal
Wallis Tests, wherever applicable.
A Likert-type scale was used to evaluate the respon-
dent’s knowledge about generic medicines being bioequiv-
alent to their reference product. Although only 2.3% of
the physicians were aware of the regulatory limits of the
bioequivalence standard in Malaysia, interestingly, 51.3%
of the respondents believed that generic products were
bioequivalent to their branded counterparts. Forty six
(17.5%) of the respondents disagreed with this statement,
and the rest remained neutral. The majority of the partici-
pants, 70.7% and 84.1%, mentioned that generic medicines
should be in same dosage form, and should have same
dose strength as the branded product, respectively. A sig-
nificant association was noted between the number of pre-
scriptions written per day, and the physicians response to
the statement that generic medicines should contain the
Table 2 Knowledge about generic medicines
Item description n (%)
Strongly disagree Disagree Neutral Agree Strongly agree
A generic medicine is bioequivalent to a brand
name medicine.
2 (0.8) 46 (17.5) 80 (30.4) 130 (49.4) 5 (1.9)
A generic medicine must be in the same dosage form
(e.g. tablet, capsule) as the brand name medicine.
0 (0.0) 30 (11.4) 47 (17.9) 146 (55.5) 40 (15.2)
A generic medicine must contain the same dose as the
brand name medicine.
0 (0.0) 16 (6.1) 26 (9.9) 159 (60.5) 62 (23.6)
Generic medicines are less effective compared to brand
name medicines. (r)
6 (2.3) 49 (18.6) 72 (27.4) 93 (35.4) 43 (16.3)
Generic medicines produce more side effects compared
to brand name medicines. (r)
8 (3.0) 103 (39.2) 100 (38.0) 45 (17.1) 7 (2.7)
Brand name medicines are required to meet higher standards
than generic medicines. (r)
5 (1.9) 31 (11.8) 32 (12.2) 137 (52.1) 58 (22.1)
There are too many generic brands available. 0 (0.0) 15 (5.7) 35 (13.3) 154 (58.6) 59 (22.4)
Generics are cheaper for patients than original brands. 0 (0.0) 0 (0.0) 7 (2.7) 123 (46.8) 133 (50.6)
It is easier to remember brand names, rather than generic
drug names.
3 (1.1) 39 (14.8) 39 (14.8) 139 (52.9) 43 (16.3)
Patients prefer original brands, they get confused
with generics. (r)
1 (0.4) 42 (16.0) 54 (20.5) 143 (54.4) 23 (8.7)
Pharmacists should dispense generic brands,
if patient agrees.
21 (8.0) 76 (28.9) 68 (25.9) 91 (34.6) 7 (2.7)
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The Bonferroni correction at 0.0083 level of significance
revealed that the difference was between the respondents
who wrote less than 10 prescriptions per day as they
expressed stronger agreement to this statement when
compared to the physicians who wrote 21–39 prescrip-
tions per day (U=1743.50, r=−0.17, p=0.007).
51.7% of the physicians stated that generic medicines
are less effective when compared to their reference prod-
uct, whereas 27.4% of the respondents remained neutral
and 20.9% disagreed with this statement. A significant as-
sociation was found among the number of prescriptions
written per day, the percentage of generic medicines in
stock, and the physician’s views on the low effectiveness of
generic medicines when compared to branded products
[H(3)=13.973, p=0.003] and [H(3)=25.179, p<0.0001], re-
spectively. For the number of prescriptions written per
day, a Bonferroni correction at a 0.0083 level of signifi-
cance revealed that the respondents who wrote < 10
prescriptions per day, expressed a stronger agreement
to the statement, when compared to the doctors who
wrote > 40 prescriptions per day [U=1541.00, r=−0.21,
p=0.001] and 21–39 prescriptions per day [U=488.50,
r=−0.17, p=0.006], respectively. The physicians working
within hospitals who had less than 10% of stock of generic
medicines in their hospital pharmacies, expressed a stron-
ger agreement to the above statement when compared to
the hospitals having 11%-40% or 41%-60% of generic med-
icines of their total stock [U=4073.50, r=−0.23, p<0.001]
and [U=1126, r=−0.25, p<0.001] respectively.Their beliefs about the low efficacy of generic medi-
cines is further supported by another notion that the
branded products are required to meet higher standards
than generic medicines and 74.2% of the physicians
thought in this way. This declaration was rejected by only
13.7% of the respondents. Of the respondents, 42.2%
(n=111) believed that generic medicines do not have more
side effects when compared to the originator products
while almost 38.0% of the clinicians were in the neutral
category. A significant association was found between the
age of the respondents and their views on this aspect, [H
(4)=18.160, p=0.001]. A Bonferroni correction at a 0.005
level of significance revealed that the physicians who were
aged between 30–40 years expressed a stronger agreement
to the statement when compared to those who were
aged between 51–60 years [U=715.50, r=−0.24, p<0.001].
However, the opposite scenario was observed while apply-
ing a Bonferroni correction at a 0.005 level of significance,
which revealed that the doctors who were aged between
41–50 years expressed a stronger agreement to the state-
ment when compared to those who were 30–40 years old
[U=1979.00, r=–0.22, p<0.001].
The majority of physicians (n=213, 81%) believed that
there were too many generic medicines available and
63.1% of the respondents confirmed that the patients pre-
ferred the originator products and they got confused
about generic medicines. A significant association was also
observed between the ages, the years of practice, and their
views on this statement. The values were [H(4)=29.647,
p<0.001] and [H(5)=29.475, p<0.001], respectively. A
Table 3 Comparison between demographic characteristics and knowledge towards generic medicines












A generic medicine is bioequivalent to a brand name medicine. 0.240 0.764 0.906 0.244 0.322 0.366 0.005 0.285
A generic medicine must be in the same dosage form (e.g. tablet,
capsule) as the brand name medicine.
0.085 0.491 0.390 0.572 0.717 0.595 0.251 0.174
A generic medicine must contain the same dose as the brand
name medicine.
0.039 0.503 0.220 0.327 0.450 0.461 0.048a 0.261
Generic medicines are less effective compared to brand name
medicines. (r)
0.265 0.239 0.915 0.100 0.436 0.047 0.003a 0.000a
Generic medicines produce more side effects compared to
brand name medicines. (r)
0.535 0.001a 0.058 0.974 0.777 0.087 0.041 0.046
Brand name medicines are required to meet higher standards
than generic medicines. (r)
0.510 0.050 0.559 0.120 0.426 0.046 0.144 0.147
There are too many generic brands available. 0.105 < 0.001a 0.084 0.207 0.541 < 0.001a 0.019 0.452
Generics are cheaper for patients than original brands. 0.183 0.418 0.396 0.077 0.360 0.213 0.274 0.029
It is easier to remember brand names, rather than generic
drug names.
0.041 0.005a 0.007 0.629 0.150 < 0.001a 0.018a < 0.001a
Patients prefer original brands, they get confused with
generics. (r)
0.171 0.385 0.883 0.930 0.293 0.573 0.117 0.002a
Pharmacists should dispense generic brands, if patient agrees. 0.221 0.121 0.099 0.921 0.413 0.598 0.420 0.028
(r): Reversed ítem. *Mann Whitney test, **Kruskal Wallis test was used. P < 0.05 is considered significant. aSignificant after Bonferroni correction.
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vealed that the respondents who were aged between 30–
40 years expressed a stronger agreement to the statement
when compared to the respondents who were between
51–60 years of age [U=711.00, r=−0.26, p<0.001]. How-
ever, the respondents who were 41–50 years of age
expressed a stronger agreement to the statement when
compared to the physicians who were between 30–40
years of age [U=1664.00, r= −0.31, p<0.001]. For the years
of practice, a Bonferroni correction at a 0.00357 level of
significance revealed that the respondents who had prac-
tised between 21–25 years expressed a stronger agreement
to the statement than the physicians who had had between
6–10 years of practice [U=172.50,r=−0.20, p=0.001]. The
physicians with 16–20 years of experience expressed a
stronger agreement to the statement when compared to
those who had been practising between 6–10 years
[U=317.50, r=−0.20, p=0.001]. The prescribers with 11–15
years of practising experience expressed a stronger agree-
ment to the statement than those who had had 21–25
years [U=652.00, r=−0.23, p<0.001] and 16–20 years of
practice [U=1167.50, r=−0.25, p<0.001]. A significant as-
sociation was also observed between the stock of generic
medicines held in their hospital pharmacy and the state-
ment that ‘Patients prefer original brands, they get con-
fused with generics’ [H(3)=15.053, p=0.002]. A Bonferroni
correction at a 0.0083 level of significance revealed that
the doctors working within hospitals having less than 10%
and 11%-40% of generic medicines in stock expressed a
stronger agreement to the statement than those who had
41%-60% of generic medicines in stock [U=1237.50, r=
−0.23, p<0.001] and [U=661.50, r=−0.20, p=0.001], re-
spectively. 69.2% of the physicians confirmed that it was
easier for them to remember the brand names than the
generic drug product names. But, at the same time, 97.4%
of the physicians appreciated that generics are cheaperTable 4 Perceptions of prescribers to issues pertaining to gen
Item description n (%)
Strongly
I believe we need a standard guideline to both prescribers
and pharmacist on brand substitution process
1 (0.4)
In my opinion, quality use of generic medicines among
patients can be achieved if both prescribers and
pharmacist work together
1 (0.4)
I think patient should be given an enough information
about generic medicines in order to make sure they really
understand about the medicines they take
1 (0.4)
I believe advertisement by the drug companies will influence
my future prescribing pattern
1 (0.4)
I need more information on the issues pertaining to the
safety and efficacy of generic medicines
0 (0.0)
Hospital budget for drug procurement factor will affect
my choice of medicines
0 (0.0)than the originals. 36.9% of the physicians denied provid-
ing a liberty to the pharmacist for dispensing generic med-
icines and 25.9% preferred to stay neutral about this idea.
The perceptions of the physicians towards issues
pertaining to generic medicines utilisation
Tables 4 and 5 show the detailed responses of the partic-
ipants regarding these issues, and the possible differ-
ences in their beliefs about generic product utilisation in
Malaysia. These were assessed by testing the effects of
demographic characteristics using Mann Whitney and
Kruskal Wallis tests, wherever applicable. Approximately
245 (93.1%) of the respondents believed that they need
standard guidelines, for both the prescribers and the
pharmacists on brand substitution. 90.5% of the respon-
dents felt that the quality use of generic medicines
among patients can be achieved, if both prescribers and
pharmacists work together. A similar percentage of phy-
sicians felt the need to provide more information about
generic medicines to patients, in order to make sure that
they understood about their medicine. A significant as-
sociation was noted between the age, the years of prac-
tice and to the above statement, [H(4)=21.148, p<0.001]
and [H(5)=24.263, p<0.001], respectively. A Bonferroni
correction at 0.005 level of significance revealed that the
doctors aged between 30–40 years expressed a stronger
agreement when compared to the respondents aged be-
tween 61 to 70 years and 51 to 60 years [U=442.00,
r=−0.19, p=0.002] and [U=876.00, r=−0.18, p=0.004], re-
spectively. The response expressed by the physicians
having an age from 41–50 years was stronger than the
30–40 years old physicians [U=1923.50, r= −0.26,
p<0.001]. For year of graduation, Bonferroni correction
at 0.005 level of significance revealed that the respon-
dents who graduated before year 1980, from 1981–1990
and between 1991–2000 expressed stronger agreementeric medicines utilization
disagree Disagree Neutral Agree Strongly agree
3 (1.1) 14 (5.3) 145 (55.1) 100 (38.0)
3 (1.1) 21 (8.0) 181 (68.8) 57 (21.7)
8 (3.0) 16 (6.1) 176 (66.9) 62 (23.6)
66 (25.1) 87 (33.1) 97 (36.9) 12 (4.6)
8 (3.0) 12 (4.6) 158 (60.1) 85 (32.3)
23 (8.7) 62 (23.6) 132 (50.2) 46 (17.5)
Table 5 Comparison between demographic characteristic and doctors’ perceptions about issues pertaining to generic medicines utilization












I believe, we need a standard guideline to both prescribers
and pharmacist on brand substitution process.
0.298 0.112 0.254 0.296 0.002 0.178 0.425 0.446
In my opinion, quality use of generics among patients can
be achieved if both prescribers and pharmacist work together.
0.071 0.255 0.392 0.024 0.126 0.110 0.407 0.560
I think, patient should be given enough information about
generic medicines in order to make sure they really understand
about the medicines they take.
0.022 < 0.001a < 0.001 0.612 0.775 < 0.001a 0.083 0.189
I believe advertisement by the drug companies will influence
my future prescribing pattern.
0.072 0.315 0.021a 0.289 0.726 0.026 0.765 0.045
I need more information on the issues pertaining to the safety
and efficacy of generic medicines.
0.005 0.007a 0.119 0.781 0.255 0.059 0.981 0.093
Budget for drug procurement will affect my choice of
medicines.
0.010 0.008a < 0.001a 0.034 0.302 0.003a 1.000 0.052
*Mann Whitney test.
**Kruskal Wallis test was used.
P < 0.05 is considered significant.
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2006 to 2010 respectively [(U=90.00, r=−0.23, p<0.001),
(U=159.5, r=−0.21, p=0.001), (U=330, r=−0.22, p<0.001)].
For years of practice, Bonferroni correction at 0.00357
level of significance revealed respondents who had longer
years of practice i.e. 11–15 years, 16–20 years, 21–25
years, >25 years) expressed stronger agreement to the
statement that those who had 6–10 years of practice
respectively [(U=267.00, r=−0.22, p<0.001), (U=306.00,
r=−0.24, p<0.001), (U=165.00, r=−0.20, p=0.001),
(U=330.00, r=−0.26, p<0.001)].
The physicians who needed more information about
the safety and the efficacy of generic medicines consti-
tuted almost 92.4% of the total sample studied. An age-
related significant association [H(4)=14.077, p=0.007]
was observed about this aspect. Bonferroni correction at
0.005 level of significance revealed that the respondents
aged between 41–50 years old expressed a stronger
agreement to the statement when compared to the phy-
sicians who were aged between 30–40 years (U=2017.50,
r=−0.24, p<0.001). Only 41.5% of the respondents agreed
that drug advertisements by the manufacturers would
influence their prescribing behaviour and a significance
association was observed among year of graduation [H
(4)=11.508, p=0.021]. Bonferroni correction at 0.005
level of significance revealed that the physicians who
graduated between the years 1991–2000 expressed a
stronger agreement to the statement that advertisements
by the drug companies would influence their future pre-
scribing patterns. This agreement was stronger when
compared to the physicians who had graduated from
2006–2010 (U=339.00, r=−0.19, p=0,002).
When the respondent’s views were sought concerning
their budgets for drug procurement versus their pre-
scription decision, 67.7% of the physicians agreed that it
would affect their choice of medicine. Significant associ-
ations [H(4)=13.897, p=0.008], [H(4)=20.526, p<0.001]
and [H(5)=17.834, p=0.003] were observed between their
age, year of graduation, experience, and the physician’s re-
sponses respectively, when replying to the statement about
pharmaceuticals procurement budgets. Bonferroni correc-
tion at 0.005 level of significance revealed that the physi-
cians in the age group of 41–50 years expressed a stronger
agreement to the statement when compared to age group
of 30–40 years (U=2179.00, r=−0.18, p=0.004). Similarly,
the respondents who graduated between the years 1991–
2000 expressed a stronger agreement to the statement
when compared to the doctors who graduated between
the years 2001–2005 (U=445.50, r=−0.184, p=0.003, at
0.005 level of significance for Bonferroni correction). Fur-
ther, the Bonferroni correction at 0.00357 level of signifi-
cance showed that the doctors who were practising
between 16–20 years (U=303.50, r=−0.21, p=0.001) and
21–25 years (U=171.00, r=−0.19, p=0.002) expressed astronger agreement to the statement when compared to
those physicians who had had 6–10 years of experience.
Discussion
The response rate achieved in this survey was 35.8%.
Generally, it is more exigent to get a high response rate
from the surveys of the physicians than from the general
population surveys [33,34]. Parson et al. reported that
follow up attempts, up to 11 times in the mail surveys of
physicians, yielded less than 20% of a response when
compared to the first mailing, which accounted for up to
40% of a response [33]. Moreover, it is known that it is
more challenging to obtain high response rates especially
from physicians practicing in private healthcare sector in
Malaysia [29,35,36]. Hence, considering the cost and time,
only two attempts were made to each of the hospitals.
More importantly, it has been reported that, although
changing, physicians remained a relatively homogenous
population with regard to their knowledge, training, atti-
tudes and behavior [37,38].
The majority of the physicians who participated in this
survey indicated a very low generic medicine prescrip-
tion rate. They preferred to use originator drug products
and write their prescriptions using brand names. This
finding is consistent with the findings reported in a quali-
tative study by Kumar et al. [20]. This phenomenon was
observed in all of the age groups and was independent of
their year, their place of graduation and experience. How-
ever, in a study conducted by Chua et al. which explored
the knowledge and perceptions of general practitioners
(GPs) concerning the use of generic medicines in Penang,
Malaysia reported that prescribing generic medicines was
much more apparent among GPs with a practice of less
than 30 years. It was also reported that the country of
graduation influenced a respondent’s prescribing trend
[29]. In our study, it was interesting to note that physi-
cians with postgraduate degree tended to prescribe more
originator products than generic medicines than those
physician with only the basic medical degree (28.3% versus
18.4% respectively wrote their prescriptions by always
using a brand name product). In Chua et al.’ study, ap-
proximately 85% of GPs were actively prescribing generic
medicines. The higher use of generic medicines among
the GPs can be correlated to the high mark ups in the cost
of the medicines, as dispensed by these doctors, in order
to make more profit [16]. Generic medicines, being
cheaper, provide more opportunity to be sold at a higher
price, since there is no drug price control in Malaysia
[17,18]. However, in private medical centres, physicians
tend to prescribe branded products since the profit from
the sale of medicines in these hospitals does not come to
the physicians. This is different from the situation in GP
clinics because in GPs clinics the profit goes directly to
them as they are the owners of these clinics. Thus,
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GPs rather than physicians from private medical centres.
In this study, we can infer that irrespective of age category,
experience, and the place of graduation, the physicians
working in the private medical centres of Malaysia prefer
to use branded medicines in their practice, and their con-
duct is affected, depending on their knowledge, their be-
liefs and their perceptions about generic medicines.
In the qualitative study by Kumar et al., it was re-
ported that the physicians interviewed had a general idea
about bioequivalence [20], but this quantitative study
provides further insight in this topic. 97.7% of the physi-
cians were unaware of the bioequivalence criteria for
generic medicines set by the Malaysian Regulatory Agency
i.e. the NPCB. This finding is similar to those reported
from other countries where the physicians had a poor
knowledge of the bioequivalence acceptability criteria set
by their respective drug regulatory agencies [26,39].
Hence, both the qualitative and quantitative studies, in-
volving physicians from the private medical centres in
Malaysia, revealed that the respondents have a rough idea
about bioequivalence, and its role in the generic industry,
but they lacked a detailed knowledge about this subject.
Surprisingly, 51.3% of the respondents considered that
generic products are bioequivalent, but still 74% (combin-
ing both always and usually categories) prefer to write
their prescriptions using brand names. This can be corre-
lated to the statement given by the physicians in the above
quoted qualitative study, about the fact that the “GPs have
been using generic medication and the patient did not get
the required relief. Now, he or she (the patient) has come
to a private hospital, and we change the medication, use
originators, because we prefer to give them better treat-
ment” [20]. In addition, 74.2% of the physicians assumed
that the manufacturing and the quality control standards
of branded products are much higher than generic medi-
cines. 51.7% of the respondents stated that generic medi-
cines are less effective when compared to their branded
counterpart. The results of such perceptions are also
depicted from the availability of very low stock (<10%) of
generic medicines in the pharmacies of their hospitals. A
typical trend was observed in the stock of generic medi-
cines and their belief in the statement that generic medi-
cines have a low efficacy when compared to branded
products (less than 10% of generic stock > 11-40% > 41-
60%). 81% of the physicians thought that there are too
many generic brands available and 63.1% of them have
commented that it leads to confusion among patients.
The lack of understanding about the regulatory require-
ments of generic drug manufacturing, and these percep-
tions, can have a negative impact on generic medicine
prescribing [29]. Thus, the findings of this study indicate a
strong need for awareness or educational programmes re-
garding generic medicines. It is of utmost importance thatgeneric medicine awareness should not only be imparted
to consumers, but also to the prescribers. The awareness
campaigns coordinated by NPCB with focus on bioequiva-
lence and cGMP requirements for generic medicines will
be of great help.
The participating physicians also expressed the need
for a standard guideline on brand substitution. The im-
plementation of such a guideline, for both physicians and
pharmacists, on generic substitution, would further en-
courage the use of generics, and maintain the accessibility
and the affordability of medicines [40]. Generic substitu-
tion policies, in many countries, allow the pharmacists to
dispense a different brand of the drug, even when the pre-
scription is written for a particular brand [41]. The imple-
mentation of the Malaysian National Medicine Policy [42]
and the nationwide policy of substituting originator or
patented drugs with generic medicines, at government
hospitals, are a step forward taken by the Malaysian gov-
ernment; but its healthcare system still lacks actual gen-
eric substitution policies, which should be implemented in
all kinds of medical facilities including the private sector
[18]. The surveyed physicians also agreed that it was im-
portant to establish a greater collaboration between them
and the pharmacists, in order to improve generic utilisa-
tion among consumers. They also articulated the need to
provide more information to the patients about generic
medicines. This complements the efforts of the Malaysian
government to spread generic medicine awareness through
nationwide road shows, as a cost containment strategy
[20,32]. Previous studies conducted in Malaysia have also
revealed that the majority of consumers do not have a fair
idea about generics [43]. Hence, high end educational in-
terventions can potentially augment the usage of gen-
eric medicines in the private medical hospitals, by
reaching both the physicians and the consumers. Stud-
ies have revealed that educational interventions on gen-
eric drugs have increased their utilisation by medicine
consumers [44]. Efforts should be made to educate and
to persuade physicians, in the early stage of their career,
about the benefits and the value of generic medicine
prescribing [25,32,45]. An increased knowledge of con-
sumers about generic medicines can also help them to
request generic medicine when they visit such medical
centres. This might result in an improved adherence
and significant savings to the OOPPs [20,46]. A signifi-
cant number of participants agreed that their selection
of medicine was influenced by drug advertising, but the
advertising should be based on hard evidence or a study.
The physicians wished to see a bioequivalence report for
generic medicines, as evidence, when the medical repre-
sentatives from the generic companies come to promote
their product [20]. This is a genuine request, since cost is
a secondary factor for the private hospital physicians, and
generally, a cheaper product is the only focus for
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literatures have also reported that the prescription behav-
iour of physicians is affected by their interactions with the
pharmaceutical manufacturers [47,48]. The physicians in-
volved in this survey also requested for more information
on the issues pertaining to the safety and the efficacy of
generic medicines. This information is necessary to boost
their confidence in generic medicines. A medical repre-
sentative is the first source of information for the phys-
ician [25] who should not only be able to discuss cost,
but should also explain about the available bioequivalence,
stability, use of ‘generally regarded as safe’ (GRAS) listed
excipients and cGMP processes involved in the manufac-
turing of his company’s product. The budgets to procure
medicines, or the patient’s socio-economic condition, are
supposed to be the major factors for generic substitution
in the private hospitals in Malaysia, which was also identi-
fied in a previous qualitative study [20].
The findings from this survey suggest it is important
that the authorities and heads of the medical profession
in Malaysia take steps to enhance prescribing efficiency
building on examples in the literature [49-53]. For in-
stance, in Europe, several measures and interventions
have been undertaken to enhance prescribing of generic
medications. These measures particularly the initiatives
and interventions that aim to enhance prescribing and
dispensing of generic medications are collated under “4
Es”, i.e. education, engineering, economics and enforce-
ment [49-51]. The implementation of these measures
has successfully promoted generic medications in Europe.
Therefore, Malaysia can learn from these experiences. For
example, beside distribution of educational printed mater-
ial, more intensive strategies such as academic detailing
and monitoring of prescribing behavior coupled with feed-
back can be adopted in Malaysia. Moreover, develop-
ment of a list of non-interchangeable medications to
address the concern of bioequivalence and therapeutic
equivalence is recommended in the literature [53,54].
Furthermore, international non-proprietary name (INN)
prescribing is one of the measures adopted in several
countries to promote generic medications (e.g. in the UK,
Lithuania and Estonia) [50]. This is important given that
INN prescribing is currently not a common practice in
Malaysia [55]. More importantly, from other countries ex-
periences, it is evident that a combination of measures is
needed to promote utilization of generic medicines rather
than a single measure [49,51,54]. Moreover, the promo-
tion efforts need to target all the involved parties including
physicians, pharmacists and patients [56].
Limitations of the study
The present study is subjected to the limitations that are
relevant to surveys where postal questionnaires are used
as a tool to extract data [57]. In particular, the lowresponse rate might influence generalization of the find-
ings to the whole population. However, it is very similar to
all previous studies conducted with physicians in private
sector in Malaysia [29,35,36]. Additionally, the representa-
tiveness of the respondents’ features and responses could
not be fully evaluated, since no national data on the demo-
graphic and practice characteristics of the physicians
working within the private medical centres in Malaysia is
available. Overall, we believe that this study is valuable,
in providing a suggestive national baseline data on the
Malaysian private healthcare sector, physician’s percep-
tions, and the practices regarding generic medicines.
Conclusion
The majority of the physicians from private medical hospi-
tals in Malaysia who participated in this survey indicated a
low generic medicine prescription rate. They preferred to
use originator drug products and write their prescriptions
using brand names. This phenomenon was observed in all
of the age groups and was independent of their year, their
place of graduation and experience. The respondents had
negative perceptions about safety, quality and the efficacy
of generic medicines which could have resulted in limited
use of generic medicines in private hospitals in Malaysia.
In order to facilitate wide use of generic medicines, it is
recommended that the physicians need to be reassured,
and educated about the drug regulatory authority’s ap-
proval system, especially with regard to bioequivalence,
quality and safety. Such interventions need to be planned,
in support of, and in corroboration with the NPCB, to
make them more effective.
Apart from the policy on generic substitution, it would
also be desirable to have a national medicine pricing policy,
which controls drug prices, in both the public and private
sector. These efforts are worthwhile to reduce the drug
expenditure and improve the medicine affordability in
Malaysia.
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